New hope drug enters human testing for Tough-to-Treat cancers
NCT ID NCT07446153
Summary
This early-stage clinical trial is testing a new drug called HRS-8364 in adults with advanced solid tumors that have progressed despite standard treatments. The study aims to find a safe and effective dose and see if the drug can shrink tumors. It will enroll up to 282 participants across multiple centers.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Liaoning Cancer Hospital & Institute
Shenyang, Liaoning, 110042, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
The Sixth Affiliated Hospital, Sun-Yat-Sen University
Guangzhou, Guangdong, 510655, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.